Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241721 | 0.75 | TSHR (0.43) | TSHR | |
| Ammonia Solution, Strong SCHEMBL8999729 | 0.72 | TSHR (0.40) | TSHR | |
| SCHEMBL8231650 | 0.67 | TSHR (0.44) | TSHR | |
| SCHEMBL8230127 | 0.65 | TSHR (0.33) | TSHR | |
| SCHEMBL8246115 | 0.65 | TSHR (0.41) | TSHR | |
| SCHEMBL1348616 | 0.62 | TSHR (0.32) | TSHR | |
| SCHEMBL235460 | 0.62 | TSHR (0.32) | TSHR | |
| SCHEMBL8844869 | 0.62 | TSHR (0.35) | TSHR | |
| SCHEMBL9878846 | 0.62 | TSHR (0.32) | TSHR | |
| SCHEMBL8254761 | 0.62 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697032-B2 | Prosthetic groups attached to stannyl polymer in the synthesis of radiopharmaceuticals | UNIVERSITY OF WESTERN ONTARIO (CA) | 2014-04-15 | — | — | US | disclosed |
| US-20130323170-A1 | PROSTHETIC GROUPS ATTACHED TO STANNYL POLYMER IN THE SYNTHESIS OF RADIOPHARMACEUTICALS | UNIVERSITY OF WESTERN ONTARIO (CA) | 2013-12-05 | — | — | US | disclosed |
| US-8435492-B2 | Prosthetic groups attached to stannyl polymer in the synthesis of radiopharmaceuticals | UNIVERSITY OF WESTERN ONTARIO (CA) | 2013-05-07 | — | — | US | disclosed |
| US-8383824-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2501679-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| EP-1624901-B1 | PROSTHETIC GROUPS ATTACHED TO STANNYLATED POLYMERS FOR THE SYNTHESIS OF RADIOPHARMACEUTICALS | UNIV WESTERN ONTARIO (CA) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011061243-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20070155976-A1 | Prosthetic groups useful in the synthesis of radiopharmaceutical compounds | UNIVERSITY OF WESTERN ONTARIO (CA) | 2007-07-05 | — | — | US | disclosed |
| EP-1624901-A2 | PROSTHETIC GROUPS ATTACHED TO STANNYL POLYMER IN THE SYNTHESIS OF RADIOPHARMACEUTICALS | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005040143-A1 | 5-(2-ARYLACETAMIDO)ISOTHIAZOLE COMPOUNDS II | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2004098650-A2 | PROSTHETIC GROUPS ATTACHED TO STANNYL POLYMER IN THE SYNTHESIS OF RADIOPHARMACEUTICALS | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2004-11-18 | — | — | WO | disclosed |
| US-4563537-A | INHIBITORS OF THROMBOXANE SYNTHETASE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1986-01-07 | — | — | US | disclosed |
| US-4520207-A | REACTING THE ADDITION PRODUCT OF A THIENYLPALLADIUM COMPLEX AND BICYCLIC OLEFIN WITH A LITHIUM ACETYLIDE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1985-05-28 | — | — | US | disclosed |
| US-4436934-A | SYNERGISTIC COMBINATION WITH ANAGRELIDE; THROMBOXANE SYNTHETASE INHIBITORS | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1984-03-13 | — | — | US | disclosed |
| US-4351949-A | Bicyclic prostaglandin analogs and method of synthesis | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1982-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HCCS, EIF2AK2, RNASE1 | TSHR 3238/4885 |
| US-20130323170-A1 | PROSTHETIC GROUPS ATTACHED TO STANNYL POLYMER IN THE SYNTHESIS OF RADIOPHARMACEUTICALS | TERT, CD47, PAICS | TSHR 128/4885 |
| US-20070155976-A1 | Prosthetic groups useful in the synthesis of radiopharmaceutical compounds | PAICS, TERT, PNMT | TSHR 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.